drugset / Trial / NCT04649723
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
Non-randomizedSequentialOpen-labelTreatment
Summary
This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers.
Timeline
- Start
- 2020-11-24
- Primary completion
- 2020-12-14
- Completion
- 2020-12-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDRALBRUTINIB | Small molecule | 200 mg | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.